Immunosuppressive drugs and highly active Antiretroviral therapy: Pharmacokinetic interactions

被引:1
|
作者
Moretto, Johnny [1 ]
Bessard, Germain [1 ]
Stanke-Labesque, Francoise [1 ]
机构
[1] Univ Grenoble 1, Ctr Hosp, Univ Med, INSERM ERI017,Lab HP2,Lab Pharmacol Toxicol, Grenoble, France
来源
THERAPIE | 2007年 / 62卷 / 04期
关键词
drug interactions; HIV; transplantation; immunosuppressive; drugs;
D O I
10.2515/therapie:2007060
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immunosuppressive Drugs and Highly Active Antiretroviral Therapy: Pharmacokinetic Interactions. The development of highly active antiretroviral therapy has greatly improved HIV-infected patient survival. However, the increased life expectancy associated with the management of opportunistic infections might favour the onset of severe organic failure that could require organ transplantation. The use of immunosuppressive drugs in association with antiretroviral therapy will generate pharmacodynamic and pharmacokinetic interactions. In this context, therapeutic drug monitoring is of great importance to improve therapeutic management of patients.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [41] Dealing with the obstacles in adhering to highly active antiretroviral therapy
    Hubbard, M
    [J]. JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2006, 17 (01): : 18 - 25
  • [42] Cytomegalovirus retinitis in the era of highly active antiretroviral therapy
    Zegans, M
    Marsh, B
    Walton, RC
    [J]. INTERNATIONAL OPHTHALMOLOGY CLINICS, 2000, 40 (02) : 127 - 135
  • [43] Neurocognitive dysfunction in the highly active antiretroviral therapy era
    Mothobi, Nomvuyo Z.
    Brew, Bruce J.
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (01) : 4 - 9
  • [44] HIV transmission under highly active antiretroviral therapy
    Vernazza, Pietro
    Hirschel, Bernard
    Bernasconi, Enos
    Flepp, Markus
    [J]. LANCET, 2008, 372 (9652): : 1806 - 1807
  • [45] Exploring the benefits and limits of highly active antiretroviral therapy
    D'Aquila, R
    Walker, B
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (17): : 1668 - 1669
  • [46] Immune reconstitution with highly active antiretroviral therapy.
    Autran, B
    Carcelain, C
    Renaud, M
    Li, TS
    Gorochov, G
    Tubiana, R
    Calvez, V
    Agut, H
    Leibowitch, J
    Katlama, C
    Debré, P
    [J]. AIDS, 1998, 12 : S2 - S2
  • [47] Maintaining infants and children on highly active antiretroviral therapy
    Rabie, Helena
    Marais, Ben J.
    Cotton, Mark F.
    [J]. SOUTH AFRICAN FAMILY PRACTICE, 2006, 48 (08) : 55 - 60
  • [48] Lipodystrophy and metabolic complications of highly active antiretroviral therapy
    Parakh, Ankit
    Dubey, Anand Prakash
    Kumar, Ajay
    Maheshwari, Anshu
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2009, 76 (10): : 1017 - 1021
  • [49] Determining the relative efficacy of highly active antiretroviral therapy
    Louie, M
    Hogan, C
    Di Mascio, M
    Hurley, A
    Simon, V
    Rooney, J
    Ruiz, N
    Brun, S
    Sun, E
    Perelson, AS
    Ho, DD
    Markowitz, M
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (06): : 896 - 900
  • [50] Lipodystrophy and metabolic complications of highly active antiretroviral therapy
    Ankit Parakh
    Anand Prakash Dubey
    Ajay Kumar
    Anshu Maheshwari
    [J]. The Indian Journal of Pediatrics, 2009, 76 : 1017 - 1021